甲磺酸伊马替尼治疗慢性粒细胞白血病30例临床观察  

Efficacy of imatinib in treatment of 30 cases with chronic myeloid leukemia

作　　者：陈文婷[1] 姚红霞[1] 

机构地区：[1]海南省人民医院血液内科,海南海口571100

出　　处：《中国热带医学》2015年第6期740-742,共3页China Tropical Medicine

摘　　要：目的观察甲磺酸伊马替尼治疗慢性粒细胞白血病(CML)的临床疗效。方法收集并分析海南省人民医院血液内科诊治的30例慢性粒细胞白血病患者,使用甲磺酸伊马替尼进行治疗,并监测临床疗效及不良反应等情况。结果完全血液学缓解(CHR)率在CML慢性期患者为93.3%,进展期为40%;主要细胞遗传学缓解(MCy R)率在CML慢性期患者为86.7%,进展期为33.3%;完全分子学缓解(CMOR)率在CML慢性期患者为80%,进展期为20%;两组患者之间差异有统计学意义(P<0.05)。CP患者1年、2年、3年、5年生存率分别为100%、94.7%、89.8%和86.5%,无进展生存率分别为92.7%、85.3%、82.6%和70.6%;AP患者1年、2年、3年生存率分别为91.5%、38.1%和37.2%,预期无进展生存率分别为39.1%、29.3%和18.6%;BP患者1年、2年的预期生存率分别为84.1%、31.7%。CP患者生存率及无进展生存率高于AP、BP患者(P<0.05)。结论甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期患者的临床疗效优于加速期和急变期。Objective To evaluate the efficacy of imatinib in treatment of chronic myeloid leukemia （CML） in adult patients. Methods A total of 30 adult CML patients collected from Hainan People＇ s Hospital were treated with oral imatinib, the efficacy and adverse reactions in the cases were observed. Results Complete hematological remission was recorded in 93.3% of patients at chronic phase （CP）and 40% of patients at progressive stage （AP＋BP）, major cytogenetic response was noticed in 86.7% of CP patients and 33.3% of patients at progressive stage （AP＋ BP）, complete molecular response was observed in 80% of CP patients and 20% of patients at progressive stage （AP ＋ BP）. There were statistically significant differences between the two groups（P〈0. 05）. The estimated 1,2,3 and 5 year overall survival（OS）rates of CP patients were 100%, 94.7%, 89.8 % and 86.5%, respectively. The estimated 1,2, 3 and 5 year progression free survival （PFS）rates were 92.7%, 85.3%, 82.6% and 70.6%, respectively. The estimated 1,2, 3 year OS rate of patients at accelerated phase were 91.5%,38.1% and 37.2% and the PFS rate were 39.1%,29.3% and 18.6%,respectively. The estimated land 2 year OS rate for BP patients were 84.1%and 31.7% respectively. The OS and PFS rates of CP patients were significantly higher than that of AP and BP patients （P〈0.05）. Conclusion The efficacy of imatinib in treatment of CML patients at chronic phase is significantly superior to that of patients at accelerated phase and blast phase.

关 键 词：伊马替尼 慢性粒细胞白血病 临床疗效 

分 类 号：R557[医药卫生—血液循环系统疾病]